Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.50 |
| ▸ | REN | P00797 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PEPD | P12955 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MVD | P53602 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041423 | 0.95 | ACE (0.55) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL18897070 | 0.86 | ACE (0.56) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL9171568 | 0.86 | ACE (0.56) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL3736446 | 0.83 | ACE (0.49) | ACEACE2 | |
| SCHEMBL13041397 | 0.82 | FKBP1A (0.56) | HSD17B10KDM4E | |
| SCHEMBL4177769 | 0.81 | ACE (0.62) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL4189532 | 0.81 | ACE (0.62) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL11995957 | 0.81 | ACE (0.62) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL13041430 | 0.81 | DPP4 (0.46) | ACE | |
| SCHEMBL13041390 | 0.80 | HPGD (0.49) | HSD17B10CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-7338969-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070208012-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070203128-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070184014-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197492-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ACE 2788/4885REN 2213/4885LMNA 2846/4885 |
| US-20070203128-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ACE 2788/4885REN 2213/4885LMNA 2846/4885 |
| US-20070093534-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | ACE 4710/4885REN 2359/4885LMNA 3949/4885 |
| US-20070208012-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ACE 2788/4885REN 2213/4885LMNA 2846/4885 |
| US-20100280034-A1 | Modulation of pathogenicity | NR1H4, NR1I3, NR1H2 | ACE 4710/4885REN 2359/4885LMNA 3949/4885 |
| US-20070184014-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | ACE 2788/4885REN 2213/4885LMNA 2846/4885 |
| US-20070196340-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | ACE 4710/4885REN 2359/4885LMNA 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.